The introduction of biologics, especially tumour necrosis factor (TNF) inhibitors, has
revolutionized the management of chronic inflammatory diseases. However, at least one …

Background Rheumatoid arthritis (RA) is a common inflammatory condition that typically
causes a symmetrical chronic arthritis that causes joint pain, swelling and in some cases a …

Although the introduction of tumor necrosis factor (TNF) inhibitors represented a significant
advance in the treatment of rheumatoid arthritis (RA), traditional anti-TNFα antibodies are …

Background Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat
rheumatoid arthritis, but whether use of a different TNFα inhibitor can improve patient …

Objective To investigate how antibodies against anti-tumour necrosis factor (anti-TNF)
agents influence response after switching from infliximab to adalimumab in rheumatoid …

Despite conventional treatment, RA still has many deleterious consequences. F rom the
patients' perspective, these include persistent pain, functional disability, fatigue, and …

Objective To assess the effectiveness of switching to a second tumour necrosis factor
inhibitor (TNFi) in patients with ankylosing spondylitis (AS). Methods Data were extracted …

Objective Anti–tumor necrosis factor (anti‐TNF) therapies are highly effective in rheumatoid
arthritis (RA) and psoriatic arthritis (PsA), but a significant number of patients exhibit only a …

Objective. To evaluate the effectiveness and safety of adalimumab in patients with
rheumatoid arthritis (RA) who previously discontinued tumour necrosis factor (TNF) …

Objectives. To study treatment response rates of RA patients undergoing second-and third-
line anti-TNF therapy and to identify baseline predictors of response to second-line …